3.38
3.38 (0%)
As of Feb 14, 2025
Compass Therapeutics, Inc. [CMPX]
Source:
Company Overview
Compass Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.
| Country | United States |
| Headquarters | boston, massachusetts |
| Phone Number | 617-500-8099 |
| Industry | manufacturing |
| CEO | Vered Bisker-Leib |
| Website | www.compasstherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.9 |
| Operating Profit | $-56.6 |
| Net Income | $-49.4 |
| Net Cash | $19.3 |
Profit Ratios
| Gross Margin | $0.9 |
| Operating Margin | -6,661.8 |
| Profit as % of Revenues | -1.7% |
| Profit as % of Assets | -33.2% |
| Profit as % of Stockholder Equity | -39.4% |
Management Effectiveness
| Return on Equity | -39.4% |
| Return on Assets | -35.2% |
| Turnover Ratio | 0.6% |
| EBITA | $-56.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $140.4 |
| Total Liabilities | $15.2 |
| Operating Cash Flow | $-44.9 |
| Investing Cash Flow | $46.8 |
| Financing Cash Flow | $17.3 |
